These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2959675)

  • 1. Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection.
    Brett MA; Dierdorf HD; Zussman BD; Coates PE
    J Chromatogr; 1987 Aug; 419():438-44. PubMed ID: 2959675
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid method for determination of ketanserin, a novel antiserotonin drug, by high-performance liquid chromatography.
    Simon V; Somani P
    J Chromatogr; 1982 Oct; 232(1):186-91. PubMed ID: 7142329
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics and presystemic hepatic first-pass elimination of a novel sigma receptor antagonist, DuP 734, in the rat.
    Kapil RP; Lam GN
    Drug Metab Dispos; 1995 May; 23(5):603-6. PubMed ID: 7587939
    [No Abstract]   [Full Text] [Related]  

  • 4. Size determination of binding polymers for [3H]imipramine and [3H]paroxetine in human platelet membranes.
    Mellerup ET; Plenge P; Nielsen M
    Eur J Pharmacol; 1984 Nov; 106(2):411-3. PubMed ID: 6099278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study.
    Sindrup SH; Grodum E; Gram LF; Beck-Nielsen H
    Ther Drug Monit; 1991 Sep; 13(5):408-14. PubMed ID: 1835549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine.
    Okonkwo PO; Reimann IW; Woestenborghs R; Klotz U
    J Chromatogr; 1983 Feb; 272(2):411-6. PubMed ID: 6833439
    [No Abstract]   [Full Text] [Related]  

  • 7. High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes.
    Mellerup ET; Plenge P; Engelstoft M
    Eur J Pharmacol; 1983 Dec; 96(3-4):303-9. PubMed ID: 6233162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of tetraprenylacetone in human plasma by high-performance liquid chromatography with fluorescence derivatization using dansylhydrazine.
    Seki T; Hashida N; Kanazawa T
    J Chromatogr; 1988 Feb; 424(2):410-5. PubMed ID: 3372634
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of cisapride in plasma and animal tissues by high-performance liquid chromatography.
    Woestenborghs R; Lorreyne W; Van Rompaey F; Heykants J
    J Chromatogr; 1988 Jan; 424(1):195-200. PubMed ID: 3079529
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine.
    Rowbotham DJ; Milligan K; McHugh P
    Br J Anaesth; 1991 Sep; 67(3):302-5. PubMed ID: 1911017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of paroxetine in the elderly.
    Bayer AJ; Roberts NA; Allen EA; Horan M; Routledge PA; Swift CG; Byrne MM; Clarkson A; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():85-6. PubMed ID: 2530796
    [No Abstract]   [Full Text] [Related]  

  • 12. The pharmacokinetics of paroxetine in patients with liver cirrhosis.
    Krastev Z; Terziivanov D; Vlahov V; Maleev A; Greb WH; Eckl KM; Dierdorf HD; Wolf D
    Acta Psychiatr Scand Suppl; 1989; 350():91-2. PubMed ID: 2530799
    [No Abstract]   [Full Text] [Related]  

  • 13. Ability of charcoal to prevent absorption of paroxetine.
    Greb WH; Buscher G; Dierdorf HD; von Schrader HW; Wolf D
    Acta Psychiatr Scand Suppl; 1989; 350():156-7. PubMed ID: 2530777
    [No Abstract]   [Full Text] [Related]  

  • 14. The pharmacokinetics of paroxetine in elderly depressed patients.
    Ghose K
    Acta Psychiatr Scand Suppl; 1989; 350():87-8. PubMed ID: 2530797
    [No Abstract]   [Full Text] [Related]  

  • 15. The pharmacokinetics of paroxetine in renal impairment.
    Doyle GD; Laher M; Kelly JG; Byrne MM; Clarkson A; Zussman BD
    Acta Psychiatr Scand Suppl; 1989; 350():89-90. PubMed ID: 2530798
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in separation techniques in sequence analysis of proteins and peptides.
    Deyl Z
    J Chromatogr; 1976 Aug; 127(2):91-132. PubMed ID: 786997
    [No Abstract]   [Full Text] [Related]  

  • 17. Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography.
    Härtter S; Hermes B; Szegedi A; Hiemke C
    Ther Drug Monit; 1994 Aug; 16(4):400-6. PubMed ID: 7974631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.
    Bannister SJ; Houser VP; Hulse JD; Kisicki JC; Rasmussen JG
    Acta Psychiatr Scand Suppl; 1989; 350():102-6. PubMed ID: 2530759
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites.
    Haddock RE; Johnson AM; Langley PF; Nelson DR; Pope JA; Thomas DR; Woods FR
    Acta Psychiatr Scand Suppl; 1989; 350():24-6. PubMed ID: 2530779
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical pharmacology of paroxetine in healthy subjects.
    Raptopoulos P; McClelland GR; Jackson D
    Acta Psychiatr Scand Suppl; 1989; 350():46-8. PubMed ID: 2530788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.